About the Company
allovir, inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific t cell (vst) therapies to prevent and treat devastating viral-associated diseases. the company's lead product is viralym-m, an allogeneic, off-the-shelf vst therapy, to treat bk virus, cytomegalovirus, adenovirus, epstein-barr virus, and human herpesvirus 6. its preclinical and clinical development product candidates include alvr106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; alvr109 to treat sars-cov-2 and covid-19; alvr107 for treating hepatitis b; and alvr108 to treat human herpesvirus-8, including kaposi's sarcoma, primary effusion lymphoma, and multicentric castleman's diseases. the company was formerly known as viracyte, inc. and changed its name to allovir, inc. in may 2019. allovir, inc. was founded in 2013 and is based in cambridge, massachusetts.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
131
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALVR News
ALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadli…
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) ...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVir
is investigating potential claims against AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR) and reminds investors of the March 19, 2024 deadline to seek the role of lead plaintiff in a federal ...
AlloVir Investor Deadline Approaching
There is no cost or obligation to you. New York, New York--(Newsfile Corp. - February 22, 2024) - Faruqi & Faruqi, LLP, a ...
Are Medical Stocks Lagging AlloVir (ALVR) This Year?
Has AlloVir, Inc. (ALVR) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this ...
AlloVir Inc
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with ...
AlloVir, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALVR
NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow ...
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact The Gross Law Firm
NEW YORK, March 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AlloVir, Inc.. Shareholders who purchased shares of ALVR during the class period listed are ...
AlloVir Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
AlloVir Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
AlloVir Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Loading the latest forecasts...